As of October 15, 2026 12:14am CDT, IBB (iShares Biotechnology ETF, XNAS) traded at $202.55, +2.53 (+1.26%) on the day. StockMarketLoop's Market Position model puts the current profit ratio at 35.05%, with support near $201.51 and resistance near $205.89.
Source: StockMarketLoop real-time market data (render-quotes-live). Not investment advice.
| Primary exchange (MIC) | XNAS |
|---|---|
| Listed since | 2001-02-05 |
| Shares outstanding | 51,200,000 |
| Headquarters | US |
IBB has traded between $199.04 and $203.90 in the current session, a range of $4.86. The latest price of $202.55 sits in the middle of that range (72% of the way from low to high). It opened at $201.02, a gap up of 0.50% from the prior close of $200.02. The volume-weighted average price is $202.91, and the stock is trading below it. Traders often use VWAP as a gauge of whether buyers or sellers have had the better average entry today.
| Open | $201.02 |
|---|---|
| High | $203.90 |
| Low | $199.04 |
| Previous close | $200.02 |
| Volume | 1,129,312 |
| VWAP | $202.91 |
StockMarketLoop's Market Position model estimates how the shares traded between 2026-07-17 and 2026-10-15 were bought. Its estimate of the average cost basis is $204.81; at $202.55 the stock trades 1.1% below that level. About 35.1% of those shares are estimated to be held at a profit at the current price. A figure in the middle means holders are split between gains and losses. The densest nearby clusters of cost basis sit around $201.51 (support) and $205.89 (resistance). Roughly 70% of the estimated cost basis lies between $199.04 and $211.64, and 90% between $189.73 and $214.38.
This is a model estimate built from price and volume history, not a record of actual positions.
Quote figures come from StockMarketLoop's market data feed and may be delayed; the timestamp in the summary above shows when they were observed. Company details come from public reference data. The cost-basis section is a statistical model, not a forecast. Nothing here is investment advice; see our financial disclaimer and editorial policy.